Scanfil Oyj (HEL:SCANFL)

Finland flag Finland · Delayed Price · Currency is EUR
12.50
-0.04 (-0.32%)
Apr 28, 2026, 6:29 PM EET
37.97%
Market Cap 822.04M
Revenue (ttm) 833.91M
Net Income (ttm) 42.39M
Shares Out 65.55M
EPS (ttm) 0.64
PE Ratio 19.62
Forward PE 15.97
Dividend 0.25 (1.99%)
Ex-Dividend Date Apr 27, 2026
Volume 4,760
Average Volume 9,503
Open 12.52
Previous Close 12.54
Day's Range 12.40 - 12.64
52-Week Range 8.38 - 12.88
Beta 0.65
RSI 60.06
Earnings Date Jul 16, 2026

About Scanfil Oyj

Scanfil Oyj operates as a contract manufacturer and system supplier for the electronics industry worldwide. The company provides manufacturing services, including electronics manufacturing, mechanics assembly, system integration, and production outsourcing; product development, designing, rapid prototyping, and test development; and product maintenance services comprising distribution, repair and refurbishment, cost improvement, and supply chain, as well as material procurement and logistics solutions. It also offers automation system modules, ... [Read more]

Sector Industrials
Founded 1976
Employees 4,199
Stock Exchange Nasdaq Helsinki
Ticker Symbol SCANFL
Full Company Profile

Financial Performance

In 2025, Scanfil Oyj's revenue was 797.11 million, an increase of 2.21% compared to the previous year's 779.91 million. Earnings were 40.89 million, an increase of 5.92%.

Financial Statements

News

Q1 2026 Scanfil Oyj Earnings Call Transcript

Q1 2026 Scanfil Oyj Earnings Call Transcript

1 day ago - GuruFocus

Scanfil Oyj Earnings Call Transcript: Q1 2026

Q1 2026 saw strong revenue and margin growth, driven by the MB Elettronica acquisition and robust organic expansion. All regions contributed positively, with Energy & Cleantech and Aerospace & Defense segments showing notable momentum. Guidance for 2026 is reaffirmed.

5 days ago - Transcripts

Scanfil Oyj Earnings Call Transcript: Q4 2025

Q4 2025 saw robust organic growth, major acquisitions, and capacity expansions, driving a 40% EPS increase and a proposed dividend hike. Guidance for 2026 is positive, with integration of new entities and continued organic growth as key priorities.

2 months ago - Transcripts

Scanfil Oyj Transcript: M&A announcement

The acquisition expands presence in Southern Europe, diversifies the customer base, and strengthens exposure to high-growth sectors like aerospace and defense. Financial terms include a €123 million valuation with an earn-out, and integration is supported by recent capacity investments.

3 months ago - Transcripts

Q3 2025 Scanfil Oyj Earnings Call Transcript

Q3 2025 Scanfil Oyj Earnings Call Transcript

6 months ago - GuruFocus

Scanfil Oyj Earnings Call Transcript: Q3 2025

Revenue grew over 10% year-over-year to EUR 191.3 million, with strong organic and acquired growth, robust EBITDA, and major contract wins in MedTech, Life Science, and logistics. Strategic acquisitions and investments in the US and Malaysia support future expansion.

6 months ago - Transcripts

Scanfil Oyj Earnings Call Transcript: Q2 2025

Q2 saw 3.4% revenue growth and a 7% EBITDA margin, with strong performance in Americas and APAC, and positive momentum in industrial, medtech, and defense segments. Recent acquisitions and a robust pipeline support a positive outlook, with organic growth expected to turn positive in H2.

10 months ago - Transcripts

Scanfil Oyj Transcript: M&A Announcement

The acquisition brings a strong aerospace and defense portfolio, expands reach into Southern Europe, and adds four specialized factories. Financial terms include a €73–123 million price based on performance, with integration focused on growth and leveraging synergies.

10 months ago - Transcripts

Scanfil Oyj Transcript: M&A Announcement

The acquisition expands North American operations, doubling aerospace and defense revenue and enhancing prototyping and PCB capabilities. Financial terms include an 80% stake for EUR 13.6 million, with the seller retaining 20%. Integration will begin post-regulatory approval in Q3.

11 months ago - Transcripts

Scanfil Oyj Transcript: Status Update

Celebrating its 50th anniversary, the company updated its strategy in 2024 to focus on growth, efficiency, and empowerment, while navigating a challenging year marked by customer inventory adjustments. Despite revenue headwinds, margins held steady, investments continued, and ESG progress accelerated.

1 year ago - Transcripts

Scanfil Oyj Earnings Call Transcript: Q1 2025

Q1 2025 saw stable margins and strong cash flow despite a slight revenue decline, with APAC and Americas regions driving growth. Investments in Malaysia and a robust pipeline in Energy & Cleantech and Medtech & Life Science support a positive outlook for the year.

1 year ago - Transcripts

Full Year 2024 Scanfil Oyj Earnings Call Transcript

Full Year 2024 Scanfil Oyj Earnings Call Transcript

1 year ago - GuruFocus

Scanfil Oyj Earnings Call Transcript: Q4 2024

Q4 delivered strong margins and record deal wins in Medtech and Life Science, despite a 4% revenue decline year-over-year. Full-year 2024 saw robust cash flow, reduced inventory, and a strengthened balance sheet, with 2025 guidance projecting renewed growth and continued focus on operational efficiency.

1 year ago - Transcripts

Scanfil Oyj Earnings Call Transcript: Q3 2024

Q3 saw EUR 41.7 million in new contracts and resilient 7.2% margins despite an 18.6% revenue drop. The acquisition of SRXGlobal expands reach, while strong cash flow and improved inventory position support a positive outlook for Q4 and beyond.

1 year ago - Transcripts

Scanfil Oyj Transcript: M&A Announcement

The acquisition of SRX Global expands the company’s Asia Pacific footprint, diversifies its customer base, and aligns with strategic growth objectives. Financial terms include an initial EUR 23.3 million payment and an earn-out based on profitability. Synergies are expected in supply chain and customer growth.

1 year ago - Transcripts

Scanfil Oyj Earnings Call Transcript: Q2 2024

Revenue fell 19.7% year-over-year to EUR 195.5 million, but operating profit margin held at 7.1% due to strong cost controls and efficiency gains. New project wins and positive cash flow strengthened the financial position, with MedTech and Life Science showing early signs of recovery.

1 year ago - Transcripts

Scanfil Oyj Transcript: CMD 2024

2 years ago - Transcripts